Novel therapeutic strategies for cardioprotection

Joost P. G. Sluijter; Gianluigi Condorelli; Sean M. Davidson; Felix B. Engel; Peter Ferdinandy; Derek J. Hausenloy; Sandrine Lecour; Rosalinda Madonna; Michel Ovize; Marisol Ruiz-Meana; Rainer Schulz; Linda W. Van Laake

doi:10.1016/j.pharmthera.2014.05.005

Novel therapeutic strategies for cardioprotection

Joost P. G. Sluijter, Gianluigi Condorelli, Sean M. Davidson, Felix B. Engel, Peter Ferdinandy, Derek J. Hausenloy, Sandrine Lecour, Rosalinda Madonna, Michel Ovize, Marisol Ruiz-Meana, Rainer Schulz, Linda W. Van Laake^*,

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

Abstract

The morbidity and mortality from ischemic heart disease (IHD) remain significant worldwide. The treatment for acute myocardial infarction has improved over the past decades, including early reperfusion of occluded coronary arteries. Although it is essential to re-open the artery as soon as possible, paradoxically this leads to additional myocardial injury, called acute ischemia-reperfusion injury (IRI, for which currently no effective therapy is available. Therefore, novel therapeutic strategies are required to protect the heart from acute IRI in order to reduce myocardial infarction size, preserve cardiac function and improve clinical outcomes in patients with IHD.

In this review article, we will first outline the pathophysiology of acute IRI and review promising therapeutic strategies for cardioprotection. These include novel aspects of mitochondrial function, epigenetics, circadian clocks, the immune system, microvesicles, growth factors, stem cell therapy and gene therapy. We discuss the therapeutic potential of these novel cardioprotective strategies in terms of pharmacological targeting and clinical application. (C) 2014 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	60-70
Number of pages	11
Journal	Pharmacology & Therapeutics
Volume	144
Issue number	1
DOIs	https://doi.org/10.1016/j.pharmthera.2014.05.005
Publication status	Published - Oct 2014

Keywords

Cardioprotection
Ischemia-reperfusion injury
Mitochondria
Circadian clock
Microvesicles
Growth factors
ACUTE MYOCARDIAL-INFARCTION
HEPATOCYTE GROWTH-FACTOR
ISCHEMIA-REPERFUSION INJURY
NITRIC-OXIDE SYNTHASE
MITOCHONDRIAL PERMEABILITY TRANSITION
PERCUTANEOUS CORONARY INTERVENTION
HISTONE DEACETYLASE INHIBITION
CARDIOMYOCYTE CIRCADIAN CLOCK
RANDOMIZED PHASE-1 TRIAL
GENE-EXPRESSION PATTERN

Access to Document

10.1016/j.pharmthera.2014.05.005

Cite this

@article{ecb37e041f89423da3ab5ee56c02be0b,

title = "Novel therapeutic strategies for cardioprotection",

abstract = "The morbidity and mortality from ischemic heart disease (IHD) remain significant worldwide. The treatment for acute myocardial infarction has improved over the past decades, including early reperfusion of occluded coronary arteries. Although it is essential to re-open the artery as soon as possible, paradoxically this leads to additional myocardial injury, called acute ischemia-reperfusion injury (IRI, for which currently no effective therapy is available. Therefore, novel therapeutic strategies are required to protect the heart from acute IRI in order to reduce myocardial infarction size, preserve cardiac function and improve clinical outcomes in patients with IHD.In this review article, we will first outline the pathophysiology of acute IRI and review promising therapeutic strategies for cardioprotection. These include novel aspects of mitochondrial function, epigenetics, circadian clocks, the immune system, microvesicles, growth factors, stem cell therapy and gene therapy. We discuss the therapeutic potential of these novel cardioprotective strategies in terms of pharmacological targeting and clinical application. (C) 2014 Elsevier Inc. All rights reserved.",

keywords = "Cardioprotection, Ischemia-reperfusion injury, Mitochondria, Circadian clock, Microvesicles, Growth factors, ACUTE MYOCARDIAL-INFARCTION, HEPATOCYTE GROWTH-FACTOR, ISCHEMIA-REPERFUSION INJURY, NITRIC-OXIDE SYNTHASE, MITOCHONDRIAL PERMEABILITY TRANSITION, PERCUTANEOUS CORONARY INTERVENTION, HISTONE DEACETYLASE INHIBITION, CARDIOMYOCYTE CIRCADIAN CLOCK, RANDOMIZED PHASE-1 TRIAL, GENE-EXPRESSION PATTERN",

author = "Sluijter, {Joost P. G.} and Gianluigi Condorelli and Davidson, {Sean M.} and Engel, {Felix B.} and Peter Ferdinandy and Hausenloy, {Derek J.} and Sandrine Lecour and Rosalinda Madonna and Michel Ovize and Marisol Ruiz-Meana and Rainer Schulz and {Van Laake}, {Linda W.}",

year = "2014",

month = oct,

doi = "10.1016/j.pharmthera.2014.05.005",

language = "English",

volume = "144",

pages = "60--70",

journal = "Pharmacology & Therapeutics",

issn = "0163-7258",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Novel therapeutic strategies for cardioprotection

AU - Sluijter, Joost P. G.

AU - Condorelli, Gianluigi

AU - Davidson, Sean M.

AU - Engel, Felix B.

AU - Ferdinandy, Peter

AU - Hausenloy, Derek J.

AU - Lecour, Sandrine

AU - Madonna, Rosalinda

AU - Ovize, Michel

AU - Ruiz-Meana, Marisol

AU - Schulz, Rainer

AU - Van Laake, Linda W.

PY - 2014/10

Y1 - 2014/10

N2 - The morbidity and mortality from ischemic heart disease (IHD) remain significant worldwide. The treatment for acute myocardial infarction has improved over the past decades, including early reperfusion of occluded coronary arteries. Although it is essential to re-open the artery as soon as possible, paradoxically this leads to additional myocardial injury, called acute ischemia-reperfusion injury (IRI, for which currently no effective therapy is available. Therefore, novel therapeutic strategies are required to protect the heart from acute IRI in order to reduce myocardial infarction size, preserve cardiac function and improve clinical outcomes in patients with IHD.In this review article, we will first outline the pathophysiology of acute IRI and review promising therapeutic strategies for cardioprotection. These include novel aspects of mitochondrial function, epigenetics, circadian clocks, the immune system, microvesicles, growth factors, stem cell therapy and gene therapy. We discuss the therapeutic potential of these novel cardioprotective strategies in terms of pharmacological targeting and clinical application. (C) 2014 Elsevier Inc. All rights reserved.

AB - The morbidity and mortality from ischemic heart disease (IHD) remain significant worldwide. The treatment for acute myocardial infarction has improved over the past decades, including early reperfusion of occluded coronary arteries. Although it is essential to re-open the artery as soon as possible, paradoxically this leads to additional myocardial injury, called acute ischemia-reperfusion injury (IRI, for which currently no effective therapy is available. Therefore, novel therapeutic strategies are required to protect the heart from acute IRI in order to reduce myocardial infarction size, preserve cardiac function and improve clinical outcomes in patients with IHD.In this review article, we will first outline the pathophysiology of acute IRI and review promising therapeutic strategies for cardioprotection. These include novel aspects of mitochondrial function, epigenetics, circadian clocks, the immune system, microvesicles, growth factors, stem cell therapy and gene therapy. We discuss the therapeutic potential of these novel cardioprotective strategies in terms of pharmacological targeting and clinical application. (C) 2014 Elsevier Inc. All rights reserved.

KW - Cardioprotection

KW - Ischemia-reperfusion injury

KW - Mitochondria

KW - Circadian clock

KW - Microvesicles

KW - Growth factors

KW - ACUTE MYOCARDIAL-INFARCTION

KW - HEPATOCYTE GROWTH-FACTOR

KW - ISCHEMIA-REPERFUSION INJURY

KW - NITRIC-OXIDE SYNTHASE

KW - MITOCHONDRIAL PERMEABILITY TRANSITION

KW - PERCUTANEOUS CORONARY INTERVENTION

KW - HISTONE DEACETYLASE INHIBITION

KW - CARDIOMYOCYTE CIRCADIAN CLOCK

KW - RANDOMIZED PHASE-1 TRIAL

KW - GENE-EXPRESSION PATTERN

U2 - 10.1016/j.pharmthera.2014.05.005

DO - 10.1016/j.pharmthera.2014.05.005

M3 - Literature review

C2 - 24837132

SN - 0163-7258

VL - 144

SP - 60

EP - 70

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

IS - 1

ER -

Novel therapeutic strategies for cardioprotection

Abstract

Keywords

Access to Document

Fingerprint

Cite this